Kornimate/medical-research-clean huggingface dataset:
ethanol and cannabinoid effects on simulated driving and related cognition

Conditions: Cannabis; Alcohol Effect; Driving Under the Influence of Alcohol and Other Drugs

Summary: the overarching goal of this study is to characterize the effects of ethanol and cannabinoids on simulated driving and related cognition.

to study the effects of ethanol clamped at bac 0.04% and thc (1.05 mg in a 70 kg individual) on driving.

Eligibility criteria:
inclusion criteria: * males or females 21 to 55 years of age (extremes included). * exposed to cannabis at least once. * exposed to alcohol at least once. * able to provide informed consent. exclusion criteria: * cannabis naive. * alcohol naive. * positive pregnancy screen * hearing deficits.
focus on stiffness reduction, endothelial function and autonomic nervous system

Conditions: Arterial Stiffness; Endothelial Function; Autonomic Nervous System; Acute Coronary Syndrome; Arterial Hypertension

Summary: myocardial infarction is related with endothelial function, arterial stiffness and autonomic nervous system dysfunction, but also with arterial hypertension. hypertension by itself is also related with endothelial function, arterial stiffness and autonomic nervous system dysfunction. primary aim of study is to investigate how complex cardiac rehabilitation influence endothelial function, arterial stiffness and autonomic nervous system activity according to presence or absence arterial hypertension. secondary aim is to obtain correlation between methods for the assessment of particular disorders and intercorrelation between different disorders for example endothelial function and autonomic nervous system activity.

we expect that in study groups pwv will improve better that in control group. 5% of the limit value of p \<0.05. we expect that in study groups aasi will improve better that in control group. 5% of the limit value of p \<0.05. we expect that in study groups ai will improve better that in control group. 5% of the limit value of p \<0.05. we expect that time and frequency parameters of hrv will increase in study group. 5% of the limit value of p \<0.05. we expect that parameters of hrt will improve in study group. 5% of the limit value of p \<0.05. we expect improvement in rhi in study group. 5% of the limit value of p \<0.05.

Eligibility criteria:
inclusion criteria: * after a recent troponin-positive acute coronary syndrome (within 7-30 days) treated by means of primary coronary angioplasty, * age 20-85 year old, * accepted and sign informed consent, exclusion criteria: * unstable coronary artery disease, * indications for a coronary artery bypass graft (cabg), * peripheral artery disease, * uncontrolled arterial hypertension, * ventricular and supraventricular arrhythmias in excess of 10% of all the evolutions throughout the day, * allergy to latex, * deformities or condition after the amputation of fingers, * body mass index (bmi) above 35 kg/m2, * a significant hepatic or renal failure, * infectious disease.

Keywords: arterial stiffness, endothelial function, autonomic nervous system, acute coronary syndrome, arterial hypertension, pulse wave velocity, augmentation index, arterial stiffness index, heart rate variability, heart rate turbulence, vascular endothelial growth factor, asymmetric dimethylarginine
neuropeptides and venous pelvic pain

Conditions: Pelvic Pain; Varicose Veins Pelvic; Pelvic Congestion Syndrome

Summary: mechanisms of the development of pain in chronic venous diseases (cvd), including pelvic congestion syndrome (pcs), are studied incompletely. the existing hypotheses of the occurrence of venous pelvic pain (vvp) do not allow to answer the question why some patients have no pain syndrome while others have very pronounced pain despite the same morphofunctional changes in the pelvic veins? the investigators are planning to carry out a study aimed at studying the content of calcitonin gene-related peptide (cgrp) and substance p (sp) in the serum of patients with pelvic veins and pelvic pain, and to study the relationship between the values of cgrp and sp in these patients.

the first phase of the study includes a set of 3 patient groups: the first is patients with pelvic vein dilation and blood reflux through them in combination with venous pelvic pain; the second is patients with pelvic vein dilatation without venous pelvic pain. the third, control group will include healthy female volunteers without pelvic veins and any chronic pain syndromes. at the second stage of the study, a study will be made of the levels of calcitonin gene-related peptide (cgrp) and the substance p (sp) in the serum using an elisa method. in addition, after studying the content of the cgrp and sp in the serum of volunteers, the investigators expect to obtain the reference values of these neuropeptides. in this phase of the study, a statistical analysis of the data obtained will be carried out, a correlation analysis between venous pelvic pain and the level of the cgrp and cp. the data for each patient will be entered into a specially designed patient questionnaire. it will include clinical and ultrasound data, results of elisa.

Eligibility criteria:
inclusion criteria: * the reproductive age of the woman * blood reflux in the parametric, uterine, gonadal veins * the absence of any concomitant pathology, accompanied by chronic pelvic pain exclusion criteria: * the absence of blood reflux in in the parametric, uterine, gonadal veins * the presence of diseases, the clinical course of which suggests the presence of chronic pelvic pain and other varieties of chronic pain, including migraine * pregnancy

Keywords: venous pelvic pain pelvic congestion syndrome calcitonin gene-related peptide substance p
the effects of sgc on glucose control in critically ill patients with sepsis

Conditions: Sepsis; Hyperglycemia; Critical Illness

Summary: poorly glycemic control in critically ill patients can increase their mortality, while safe and efficient glucose control is laborious and time-consuming. the space glucose control which is installed with empc(enhanced model predictive control) can get the blood glucose target range safely and effectively through regulating insulin dose rate, and decrease the glucose variability. this study is a random controlled trial involving the patients with sepsis in intensive care unit in order to evaluate the difference of safety and efficacy of blood glucose control between sgc directed and conventional treatment. at last, the trial results can determine whether the space glucose control can control blood glucose safely and effectively in the patients with sepsis in intensive care units.

design: the study was conducted as a single-centre, open randomized controlled, parallel trial. study population: adult general icu patients with sepsis and assumed to require at least 3 days of intensive care were recruited. patients fulfilling the inclusion criterion of glucose≥9.0 mmol/l were randomly assigned using serially numbered to either the intervention group (bg control by sgc) or the control group (conventional empiric bg management). the both group aim to establish the bg levels 5.8-8.9mmol/l. study protocol: bg measurements were performed using glucometer to test the fingertip capillary blood sample for the bg levels. as for patients with shock or required vasopressor, arterial bg was sampled to measure through the glucometer. insulin was infused intravenously applying the standard perfusor of the icu. average glucose, glucose variability, sofa score, apache ii score, and hla-dr were recorded. all trial-related activities were carried out until the end of the patient's icu stay, or for a period of 72 hours. meanwhile, enteral and parenteral nutrition was administrated to patients according to their condition. statistical analysis was performed on an intention-to-treat basis. the percentage of values in the target range (5.8-8.9mmol/l) was defined as primary end point for the assessment of glucose control. data are reported as mean±sd values if not otherwise indicated. data analysis was performed using spss19.0.

Eligibility criteria:
inclusion criteria: 1. admitted to the icu 2. at least one bg measurement 9.0mmol/l or higher 3. expected to stay in icu ≥3 days; 4. critically ill patients with sepsis 5. sofa score≤2 exclusion criteria: 1. aged \< 18 years; 2. admitted because of diabetic ketoacidosis or nonketotic hyperosmolar state 3. pregnant 4. in a state in which death was perceived as imminent 5. without written informed consent
chemotherapy in treating patients with locally advanced or metastatic cancer of the pancreas or bile duct

Conditions: Extrahepatic Bile Duct Cancer; Pancreatic Cancer

Summary: rationale: drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. combining more than one drug may kill more tumor cells. purpose: phase ii trial to study the effectiveness of combining gemcitabine, leucovorin, and fluorouracil in treating patients who have locally advanced or metastatic cancer of the pancreas or bile duct.

objectives: i. determine the response rate, in terms of who objectives and clinical benefit, in patients with locally advanced or metastatic pancreatic or biliary adenocarcinoma treated with gemcitabine, leucovorin calcium, and fluorouracil. ii. determine the tolerance of this regimen in this patient population. iii. determine the survival without disease progression in patients treated with this regimen. iv. determine the overall survival in patients treated with this regimen. outline: this is a multicenter study. patients receive leucovorin calcium iv over 2 hours followed by fluorouracil iv over 24 hours on day 1 followed by gemcitabine iv over 80-150 minutes on day 2. treatment repeats every 2 weeks for a minimum of 6 courses in the absence of disease progression or unacceptable toxicity. patients achieving complete response may continue chemotherapy for up to 1 year. patients with locally advanced disease after 3 months of chemotherapy may receive concurrent radiotherapy with chemotherapy for 5 weeks, or may undergo surgical resection. fluorouracil-based chemotherapy (with or without radiotherapy) may then resume after surgery. patients are followed for survival. projected accrual: a total of 14-39 patients will be accrued for this study.

Eligibility criteria:
disease characteristics: histologically confirmed pancreatic or biliary duct adenocarcinoma metastatic or locally advanced no cerebral metastasis surgically unresectable patient characteristics: age: 18 to 75 performance status: ecog 0-2 life expectancy: more than 12 months hematopoietic: absolute neutrophil count greater than 1,500/mm3 platelet count greater than 100,000/mm3 hepatic: alkaline phosphatase less than 5 times normal bilirubin less than 1.5 times normal renal: creatinine less than 1.5 times normal no uncontrolled or persistent hypercalcemia cardiovascular: no severe cardiac failure pulmonary: no severe respiratory failure other: no other malignant tumor considered incurable or untreatable no uncontrolled pain no psychological, familial, social, or geographical reasons that would preclude study prior concurrent therapy: biologic therapy: not specified chemotherapy: no prior chemotherapy endocrine therapy: no concurrent corticosteroids except as antiemetic radiotherapy: no prior radiotherapy surgery: see disease characteristics

Keywords: stage ii pancreatic cancer stage iii pancreatic cancer unresectable extrahepatic bile duct cancer adenocarcinoma of the extrahepatic bile duct adenocarcinoma of the pancreas stage iv pancreatic cancer
palliative care in improving quality of life in patients with high risk primary or recurrent gynecologic malignancies

Conditions: Cervical Carcinoma; Ovarian Carcinoma; Primary Peritoneal Carcinoma; Recurrent Cervical Carcinoma; Recurrent Ovarian Carcinoma; Recurrent Uterine Corpus Carcinoma; Recurrent Vulvar Carcinoma; Uterine Corpus Cancer; Vulvar Carcinoma; Peritoneal Neoplasms

Summary: this randomized clinical trial studies a palliative care program in improving the quality of life of patients with high-risk gynecologic malignancies that is original or first tumor in the body (primary) or has come back (recurrent). palliative care is care given to patients and their families facing the problems associated with life-threatening illness, through the prevention and relief of suffering by means of early identification and impeccable assessment and treatment of pain and other problems, physical, psychosocial and spiritual. studying a palliative care program may help doctors learn more about patients quality of life, use of healthcare services, and the relief of pain.

primary objectives: i. validate a model of proactive palliative medicine referral. ii. quantify the impact of palliative care aggressive care at the end-of-life (pcare) versus pcare + idiographic assessment on quality of care and patient satisfaction. iii. utilizing cmo data investigators will create a cost model for patients randomized to pcare versus patients refusing randomization. iv. determine the impact of a proactive model of palliative care consultation at the time of diagnosis on family/caregivers. outline: patients are randomized 1 of 2 arms. group i (usual pcare): patients complete european organization for research and treatment of cancer quality of life-30 (eortcqlq-30) and family satisfaction with advanced cancer care (famcare) questionnaire every 6 weeks for 3 visits. group ii: (usual pcare + idiographic assessment): patients complete eortc qlq-30, and famcare questionnaire as in group i and undergo idiographic assessment. beginning within 4 weeks of their visit with the gynecologic oncologist, patients are referred to outpatient palliative medicine consultation. after completion of study, patients are followed up periodically .

Eligibility criteria:
inclusion criteria: * women with of primary or recurrent diagnosis of ovarian, uterine, peritoneal, cervical or vulvar cancer with any of the following: * \< 30 % projected 5 year survival based on histopathological stage * non-pelvic recurrent malignancy * persistent or progressive disease despite primary treatment with surgery, chemotherapy or * palliative performance scale \< 60 * enrollment within 6 weeks of tumor board review
effects of nutritional strategies or manual therapies in women with fibromyalgia

Conditions: Fibromyalgia

Summary: the study had two objectives. the first main aim was to analyze the effects of tryptophan and magnesium-enriched mediterranean diet on psychological variables (trait anxiety, self-image, mood state, eating disorders) and sleep effects in women with fibromyalgia. our hypothesis, based on previous positive effects of tryptophan and magnesium supplementation by separate in this population, may improve psychological health and regulate sleep disruptions. the second aim was to assess the effectiveness of a manual therapy technique performed with moderate digital pressure in fibromyalgia patients on the variables of fatigue, pain, sleep, anxiety and mood. it was done to provide an alternative treatment to pharmacological therapies for fibromyalgia patients and to provide new evidence on the effects of manual therapy in fibromyalgia patients.


Eligibility criteria:
inclusion criteria: - women aged 40-60 with fibromialgia (officially diagnosed). exclusion criteria: * women used analgesics, vitamins containing supplements, and or other drugs for the treatment of fibromyalgia symptoms, or participation in other clinical trials. * women that be performing simultaneously to this study some other physical therapy or physical exercise treatment. not having sufficient cognitive level to collaborate in the study or not having the possibility of attending the established sessions.

Keywords: micronutrients nutrition therapy chronic disease
thoracoscopic mesh repair of diaphragmatic defects for hepatic hydrothorax

Conditions: Liver Cirrhosis

Summary: the management of refractory hepatic hydrothorax is challenging and usually unsuccessful. the study will discuss the perioperative treatment, effectiveness, and morphology of diaphragmatic defects of hepatic hydrothorax in thoracoscopic mesh repair. risk factors associated with increased three-month mortality in these critically ill patients will be studied.

objective the objective was to analyze the outcomes of thoracoscopic mesh repair for hepatic hydrothorax (hh) at the institution of the investigators during the past 10 years. methods a total of 63 patients with refractory hh, who underwent thoracoscopic mesh onlay reinforcement to repair diaphragmatic defects from january 2005 to december 2014, were included in the study. mesh covering alone was used in 47 patients and mesh with suturing was used in 16 patients. patient demographics, child-pugh class, and model for end-stage liver disease (meld) score were evaluated to predict morbidity and mortality.

Eligibility criteria:
inclusion criteria: * patients with refractory hepatic hydrothorax (\> 3 times thoracentesis and failure to maximal doses of diuretics) exclusion criteria: * patients with systemic bacteremia, positive culture of bacteria of pleural effusion or ascites were excluded from the study because of potential mesh contamination.

Keywords: hepatic hydrothorax thoracoscopic surgery diaphragmatic defect
effect of music therapy on cognitive recovery

Conditions: Epilepsy

Summary: participation in music therapy will result in improvement in cognitive functioning, as measured by neuropsychological testing 9-12 months following surgery.

music therapy could have a significant impact on clinical outcomes for patients with epilepsy. one study found that epilepsy patients who received music therapy for six months or greater had a significant reduction in number of seizures and could potentially aid in decreasing medication dosage. the investigators would like to contribute to this sort of research, but focus on what effect music therapy has on a patient's cognitive recovery after undergoing epilepsy surgery. although research exists regarding music therapy on memory and communication, its overall effect on this patient population is unclear. the dell children's epilepsy program hopes that this research project on memory and communication will have a positive effect on their patients with epilepsy.

Eligibility criteria:
inclusion criteria: * between 6-16 years of age * will undergo either a brain resection or lobectomy exclusion criteria: * pre-surgical full scale iq below 70 * primary language is not english * hearing or vision impairments * parental consent cannot be obtained

Keywords: epilepsy, seizure disorder
a randomized trial of letters from family physicians to encourage screening mammography in overdue women

Conditions: Breast Cancer

Summary: a randomized, double-blinded study conducted in british columbia, canada, where there is a publicly funded, organized screening program and screening mammography is recommended at 24-month intervals. eligible women aged 51-73 years old and overdue for their screening mammogram by 6-24 months are identified in the database of the screening mammography program of bc (smpbc). family physicians are recruited by mail and asked to sign letters to the overdue women in their practices. the overdue women are randomized and mailed either the signed reminder letter and the standard reminder postcard, or the standard reminder postcard alone. the primary endpoint is the proportion of overdue women attending a screening mammogram appointment 6 months after the mailing.


Eligibility criteria:
inclusion criteria: active family physicians (family physicians, general practitioners or primary care physicians) who have overdue women in their practice that meet the following criteria: * previously been enrolled in the smpbc and had a previous normal screening mammogram. * have agreed to being contacted for research on the smpbc questionnaire * are 6-24 months overdue from their last screening mammogram * live in bc * have listed an active family physician as the contact to receive their mammography results exclusion criteria: * family physicians who do not work in primary care * family physicians who do not have overdue women in their practice

Keywords: 6-24 months overdue screening mammography
pre-emptive analgesics in orthodontic treatment

Conditions: NSAID; Pain Management

Summary: this study is designed to determine if the preemptive use of a combination of acetaminophen and ibuprofen is more effective in reducing pain following orthodontic tooth movement when compared to the use of acetaminophen and ibuprofen alone.

this study is designed to determine if the preemptive use of a combination of acetaminophen and ibuprofen is more effective in reducing pain following orthodontic tooth movement when compared to the use of acetaminophen and ibuprofen alone. before their orthodontic appointment, participants will be administered acetaminophen (650mg), ibuprofen (400mg), or acetaminophen (650mg) + ibuprofen (400mg). participants will be asked to record their pain intensity using a numerical (0-10) visual analog scale (vas) during rest, light biting, and while chewing paraffin wax during the following time intervals: immediately following drug administration, 6 hours after, the morning after, and the second morning after orthodontic treatment.

Eligibility criteria:
inclusion criteria: -orthodontic patient presenting for orthodontic treatment exclusion criteria: * history of taking an analgesic in the past six hours * hypersensitivity to ibuprofen or acetaminophen * aspirin-sensitive asthma * renal or liver impairment * history of gi bleeding or ulcers * cardiovascular disease, recent myocardial infarction, heart failure, or coronary artery bypass graft surgery * currently taking antibiotics or other medications for a chronic systemic disease * bleeding disorder * pregnant or nursing

Keywords: pre-emptive analgesics acetaminophen ibuprofen
atezolizumab - bevacizumab in the treatment hepatocellular carcinoma inoperable or

Conditions: Advanced Hepatocellular Carcinoma

Summary: evaluation of the efficacy and safety of the combination atezolizumab - bevacizumab in the treatment of locally advanced inoperable or metastatic hepatocellular carcinoma in finistère

patients treated by atezolizumab and bevacizumab for an advanced hepatocellular carcinoma will be followed to observed their safety and the efficacy of this treatment, and to identify prongnosis factors

Eligibility criteria:
inclusion criteria: * hepatocellular carcinoma locally advanced or metastatic, non able to be resectable, with no prior systemic treatment * child pugh a and ecog 0 or 1 * upper digestiuve endoscopy less than 6 months, if esophageal varcices : must be treated * non eligible to receive a locoregional therpay or progressive after this kinf of treatment * with informed consent exclusion criteria: * refuse to participate * under legal protection * exclusion criteria from the tempory utilisation authorization

Keywords: atezolizumab, bevacizumab , advanced hepatocellular carcinoma